0.411

0.77% -0.0032

Acurx Pharmaceuticals Inc (ACXP)

Overview News Price History Option Chain Financials Discussions Forecast

Acurx Pharmaceuticals Inc stock is traded at $0.411, with a volume of 155.79K. It is down -0.77% in the last 24 hours and up +11.38% over the past month. Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Previous Close:

$0.4142

Open:

$0.415

24h Volume:

155.79K

Relative Volume:

0.60

Market Cap:

$9.65M

Revenue:

Net Income/Loss:

$-14.58M

P/E Ratio:

-0.3574

EPS:

-1.15

Net Cash Flow:

$-9.80M

1W Performance:

+11.81%

1M Performance:

+11.38%

6M Performance:

-68.38%

1Y Performance:

-85.27%

1-Day Range:

$0.41

$0.4186

1-Week Range:

$0.3606

$0.4532

52-Week Range:

$0.30

$3.325

Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile

Name

Acurx Pharmaceuticals Inc

Sector

Healthcare (1173)

Industry

Biotechnology (668)

Phone

917-533-1469

Address

259 LIBERTY AVENUE, STATEN ISLAND

Employee

Twitter

Next Earnings Date

2025-03-18

Latest SEC Filings

ACXP's Discussions on Twitter

Compare ACXP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACXP Acurx Pharmaceuticals Inc	0.411	8.63M	0	-14.58M	-9.80M	-1.15
ONC Beigene Ltd Adr	236.49	23.78B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	435.32	108.15B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.24	43.44M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	604.62	61.69B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	74.09	5.72B	0	-153.72M	-103.81M	-2.00

Acurx Pharmaceuticals Inc Stock (ACXP) Latest News

May 21, 2025

ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus

May 21, 2025

Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling StockholderSEC Filing - marketscreener.com

May 21, 2025

May 19, 2025

Q2 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World

May 19, 2025

May 17, 2025

HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World

May 17, 2025

May 16, 2025

Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment - MSN

May 16, 2025

May 15, 2025

ACXP: Acurx Pharmaceuticals Receives 'Buy' Rating from HC Wainwr - GuruFocus

May 15, 2025

H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock - Investing.com Australia

May 15, 2025

H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 T - GuruFocus

May 15, 2025

H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock By Investing.com - Investing.com India

May 15, 2025

H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 Target | ACXP Stock News - GuruFocus

May 15, 2025

May 14, 2025

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

Acurx Pharmaceuticals Reports Improved Q1 2025 Results - TipRanks

May 14, 2025

May 13, 2025

Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million - marketscreener.com

May 13, 2025

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan

May 13, 2025

May 12, 2025

Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 11, 2025

Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025

May 08, 2025

Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement - TipRanks

May 08, 2025

May 05, 2025

New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - Seeking Alpha

May 05, 2025

Apr 30, 2025

Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results - TradingView

Apr 30, 2025

Acurx Pharmaceuticals to Reveal Q1 2025 Financial Performance and Key Pipeline Updates - Stock Titan

Apr 30, 2025

Apr 28, 2025

Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan

Apr 28, 2025

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase - Yahoo Finance

Apr 28, 2025

Apr 17, 2025

Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada

Apr 17, 2025

Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com

Apr 17, 2025

Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan

Apr 17, 2025

Apr 16, 2025

Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025

New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - standard-journal.com

Apr 16, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 16, 2025

Apr 08, 2025

Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 08, 2025

Apr 06, 2025

Acurx Pharmaceuticals announces resale of 8.4M shares - MSN

Apr 06, 2025

Apr 02, 2025

10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey

Apr 02, 2025